PMID: 42251859

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Buse John B, Bajaj Harpreet S, Dalskov Stine-Mathilde, Donaldson Lucienne, Hansen Duus Helene H, Fabricius Therese Wilbek, Haluzík Martin, Lingvay Ildiko, Pedersen Sue D, Pratley Richard E

The lancet. Diabetes & endocrinology · 2026

Vol. 14, Issue 8, pp. 662-677

View on PubMed DOI

This entry links to third-party literature. For research use only.

HumansDiabetes Mellitus, Type 2SemaglutideGlucagon-Like PeptidesFemaleDouble-Blind MethodMaleMiddle AgedHypoglycemic AgentsAged

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.